Here is your NEWS-Line for Healthcare Professionals eNewsletter. For the latest news, jobs, education and blogs, bookmark our news page and job board or to take us everywhere with you, save this link to your phone. Also, enjoy the latest issue of NEWS-Line for Healthcare Professionals magazine, always free.
NEWS:
President Biden And Congress Urged to Prepare and Implement National Crisis Management Plan to Address Needs of Millions Suffering from Long COVID
The American Academy of Physical Medicine and Rehabilitation (AAPM&R) called on President Joe Biden and Congress to gear up for the next coronavirus crisis, by preparing and implementing a comprehensive national plan focused on the needs of millions of individuals suffering from the long-term symptoms of COVID-19.
According to two recent publications from the Journal of the American Medical Association, ten to thirty percent of individuals who had COVID-19 reported at least one persistent symptom up to six months after the virus left their bodies. That means 3 to 10 million Americans are experiencing symptoms of Long COVID or Post-Acute Sequelae of SARS-CoV-2 infection (PASC), which are varied and ongoing, including neurological challenges, cognitive problems such as brain fog, shortness of breath, fatigue, pain, and mobility issues.
"We have an opportunity right now to avert the next
Read Full Article
Survey Compares COVID-19 Perceptions from March 2020 vs March 2021
One-year into the COVID-19 pandemic and even with the light of the vaccine on the horizon, a majority of Americans are still fearful, according to a new healthinsurance.com national survey of 1,000 U.S. adults
62% of those surveyed say they are still afraid of getting COVID-19. In fact, 25% say they would unfriend someone if they exposed them to COVID-19. 7 in 10 say they have or know someone who has tested positive for COVID-19. 68% say they will get the COVID-19 vaccine as soon as they are eligible. A surprising finding, even once vaccinated, 62% have apprehensions about life "returning to normal".
Healthinsurance.com began conducting monthly consumer pulse surveys in March of 2020. For this month's survey, we asked five of the original questions to see if any perceptions changed. Cost of care was a concern then and is still a concern now.
41% would think twice about seeking medica
Read Full Article
Clinical Research Forum Presents Moderna and Pfizer with Award for Extraordinary Impact on Health
The Clinical Research (CR) Forum, a non-profit membership association of top clinical research experts and leaders from the nation’s leading academic health centers, announced Moderna and Pfizer as the recipients of the first ever Award for Extraordinary Impact on Health. Awards were also presented for 2021 winners of the prestigious annual Top 10 Clinical Research Achievement Awards winners this morning.
The CR Forum presented the first ever Award for Extraordinary Impact on Health, honoring exceptional clinical and translational research that benefits all peoples and nations. CR Forum presented this special honor for the scientific achievements of those at Moderna and Pfizer for the development of the individual vaccines against COVID-19. The rapid development of these vaccines shows what clinical and translational research can accomplish at its best. The researchers of both vaccines
Read Full Article
T Cells Recognize Recent SARS-CoV-2 Variants
When variants of SARS-CoV-2 (the virus that causes COVID-19) emerged in late 2020, concern arose that they might elude protective immune responses generated by prior infection or vaccination, potentially making re-infection more likely or vaccination less effective. To investigate this possibility, researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and colleagues analyzed blood cell samples from 30 people who had contracted and recovered from COVID-19 prior to the emergence of virus variants. They found that one key player in the immune response to SARS-CoV-2—the CD8+ T cell—remained active against the virus.
The research team was led by NIAID’s Andrew Redd, Ph.D., and included scientists from Johns Hopkins University School of Medicine, Johns Hopkins Bloomberg School of Public Health and the Immunomics-focused
